INTRODUCTION AND OBJECTIVES: Patients will inevitably relapse with castration-resistant prostate cancer (CRPC) after the failure of androgen deprivation therapy, and our previous studies have shown that the deficiency of DAB2IP, a well-known tumor suppressor, may be involved. Its loss will not only lead to the hyperactivation of androgen receptor (AR), but also increase AKR1C3 expression and de novo androgen synthesis. In this study, we will further unveil the mechanism of ARK1C3 gene expression regulated by DAB2IP, and explore its potential role in regulation of androgen receptor splicing variant (i.e., ARv7) expression in prostate cancer (PCa) cells.
INTRODUCTION AND OBJECTIVES: Patients will inevitably relapse with castration-resistant prostate cancer (CRPC) after the failure of androgen deprivation therapy, and our previous studies have shown that the deficiency of DAB2IP, a well-known tumor suppressor, may be involved. Its loss will not only lead to the hyperactivation of androgen receptor (AR), but also increase AKR1C3 expression and de novo androgen synthesis. In this study, we will further unveil the mechanism of ARK1C3 gene expression regulated by DAB2IP, and explore its potential role in regulation of androgen receptor splicing variant (i.e., ARv7) expression in prostate cancer (PCa) cells.
METHODS: AKR1C3 gene regulation by DAB2IP was determined in different PCa cells (C4-2, LAPC-4 and 22RV1) with lentivirus transduction, gene expression and chromatin immunoprecipitation assays. Then a series of biochemical, molecular and cell biologic methods were employed to characterize the impacts of AKR1C3 on ARv7 in PCa cells. Also, xenograft animal model and clinical specimens were used to validate in vitro results.
RESULTS: The expression of AKR1C3 gene was suppressed on the transcriptional level by DAB2IP through the inhibition of AKT/ mTOR/ETS-1 signaling. Functionally, AKR1C3 overexpression will increase the expression of ARv7 protein by forming a complex with ARv7 and then enhancing ARV7 protein stability through ubiquitin pathway, which could subsequently maintain the constitutive AR activation and PCa cell growth in the absence of androgen. Moreover, there was a significantly positive correlation between AKR1C3 and ARv7 expression in tissues from xenografts and human RCC specimens.
CONCLUSIONS: Besides the role as a critical steroidogenic enzyme in androgen synthesis, AKR1C3 upregulation triggered by upsteam signaling could also contribute to the aberrant ARv7 overexpression and CRPC development. 
MP64-13 COMBINED N-TERMINAL ANDROGEN RECEPTOR AND AUTOPHAGY INHIBITION INCREASES THE ANTI-TUMOR EFFECT IN ENZALUTAMIDE-SENSITIVE AND ENZALUTAMIDE-RESISTANT LNCAP CELLS
Benedikt Kranzb€ uhler*, Souzan Salemi, Tullio Sulser, Daniel Eberli, Zurich, Switzerland INTRODUCTION AND OBJECTIVES: Multiple androgen receptor (AR) dependent and independent resistance mechanisms limit the efficacy of current castration resistant prostate cancer (CRPC) treatment. Novel N-terminal domain (NTD) binding AR targeting components including EPI-001 have the promising ability to block constitutively active splice variants; a major resistance mechanism in CRPC. Autophagy is a conserved lysosomal degradation pathway and acts as survival mechanism in cells exposed to anti-cancer treatment. We hypothesized that also a promising NTD-AR treatment may lead to upregulation of autophagy and can be targeted by a combination treatment with autophagy inhibitors.
METHODS: Prostate cancer cell lines LNCaP and LNCaPEnzR were cultured in steroid-free medium and treated with different concentrations of EPI-001 (EPI: 10, 25, 50uM) and in combination with autophagy inhibitors chloroquine (CHQ, 20uM) or 3-methyladenine (3MA, 5mM). Cell growth was assessed by WST-1-assays after 1 and 7 days. Etidium bromide and AnnexinV were used to measure viability and apoptosis on day 7 after treatment. Autophagosome increase was detected by Autodot staining. In addition, autophagic activity was monitored by western blot (WB) and immunocytochemistry for the expression of LC3-I/II, Atg5 and Beclin1.
RESULTS: Treatment with EPI resulted in a dose dependent reduction of cell growth and increase of apoptosis on day 7 in both cell lines. Combination of 25uM EPI with autophagy inhibitors led to a further reduction of cell viability up to 17% for CHQ, 15% for 3MA in LNCaP and up to 24% for CHQ, 36% for 3MA in LNCaP-EnzR. Assessment of autophagy levels in EPI treated cells by WB showed an increase of LC3-II and no change in Beclin1 expression in both cell lines. Immunocytochemistry detected a significant increase of Atg5 and pronounced LC3-II punctuation in EPI-001 treated LNCaP and LNCaPEnzR. This was supported by an increase in autophagosome punctuation observed by Autodot staining.
CONCLUSIONS: Our data demonstrate that N-terminal androgen receptor inhibition with EPI-001 leads to increased autophagic activity in LNCaP and LNCaP-EnzR prostate cancer cells. Combination of N-terminal androgen receptor blockage with simultaneous autophagy inhibition increases the antitumor effect of EPI even in enzalutamide-resistant cells. Double treatment may offer a promising strategy to overcome resistance mechanisms in advanced prostate cancer.
Source of Funding: none

MP64-14 TARGETING HEAT SHOCK FACTOR 1 SENSITIZES CASTRATION-RESISTANT PROSTATE CANCER CELLS TO HSP90 INHIBITION IN PART BY DESTABILIZING ANDROGEN RECEPTOR SPLICE VARIANTS
Toshiki Kijima*, Tokyo, Japan; Thomas Prince, Danville, PA; Katsuo Mori, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Tokyo, Japan; Len Neckers, Bethesda, MD; Yasuhisa Fujii, Tokyo, Japan INTRODUCTION AND OBJECTIVES: The emergence of constitutively active androgen receptor (AR) splice variants lacking ligand-binding domain is an increasingly recognized resistance mechanism for AR-targeted therapies in castration-resistant prostate cancer (CRPC). Inhibition of the molecular chaperone heat shock protein (HSP) 90 could provide a multifaceted approach to target CRPC by degrading full-length AR as well as various oncoproteins that support cell survival. Yet HSP90 inhibition has been shown to be ineffective in degrading AR variants, suggesting that the stability and function of AR variants depend on other molecular chaperones. In this study, we tested whether inhibition of heat shock factor 1 (HSF1), the master transcription factor regulating all inducible HSPs, could enhance the antitumor activity of HSP90 inhibitor in a prostate cancer cell line expressing AR variants.
METHODS: We used CRPC cell line 22Rv1, which expresses both full-length AR and AR variants. We examined the effect of four HSF1 inhibitors (Quercetin, KNK437, Triptolide and KRIBB11) on protein levels of inducible HSP (HSP70), full-length AR, and AR variants. The antitumor effects of HSF1 inhibitors and HSP90 inhibitor (STA-9090) as single agents or in combination were measured by MTS assay.
RESULTS: All examined HSF1 inhibitors decreased full-length AR and AR variants. Triptolide effectively inhibited the expression of stress-inducible HSP70 and decreased both full-length and variant AR at nM concentrations. Combination with STA-9090 further decreased Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e855
